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DNA methylationIncreased expression of miR-128a is often observed in acute lymphoblastic leukaemia (ALL) compared with
its expression in acute myeloid leukaemia (AML). The objective of this study was to investigate the role of
miR-128a, especially that in the Fas-signalling pathway, in T-cell leukaemia cells. The role of miR-128a in Fas-
mediated apoptosis was examined by using Fas-activating antibody (CH-11)-susceptible Jurkat cells and
-resistant Jurkat/R cells. Whereas ectopic expression of miR-128a conferred Fas-resistance on Jurkat cells by di-
rectly targeting Fas-associated proteinwith death domain (FADD), antagonizingmiR-128a expression sensitized
Jurkat/R cells to the Fas-mediated apoptosis through derepression of FADD expression. Myeloid leukaemia HL60
andK562 cells were also CH-11-resistant, sharing a similar resistantmechanismwith Jurkat/R cells. Furthermore,
CH-11 induced demethylation of the promoter region of miR-128a with resultant up-regulation of miR-128a ex-
pression in Jurkat/R cells, whichwas shown to be amechanism for the resistance of Jurkat/R cells to Fas-mediated
apoptosis. Our results indicate that the induction ofmiR-128a expression byDNA demethylation is a novelmech-
anism of resistance to Fas-mediated apoptosis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are non-coding single-stranded RNAs of
18–25 nucleotides that have emerged as post-transcriptional regula-
tors of gene expression in a variety of biological processes such as devel-
opment, cell proliferation, differentiation, and apoptosis [1,2]. miRNAs
repress protein expression via complementary sequence recognition
in the 3′-untranslated region (3′UTR) of the target mRNAs and/or deg-
radation of the target mRNAs [3]. Their dysregulated expression has
been linked to various kinds of human diseases, including cancer [4,5].
The association between aberrant miRNA expression and cancer was
tightened by the discovery that a number of miRNAs are encoded at
‘fragile sites,’ which are unstable genomic regions involved in cancer
pathogenesis [6,7]. Epigenetic alterations such as DNA methylation
and chromatin modiﬁcation are recently also gaining more and more
attention as a mechanism of miRNA dysregulation [8–10]. As a conse-
quence of these genetic and epigenetic modiﬁcations of miRNA expres-
sion, a unique miRNA expression proﬁle for each important cancer81 58 230 7604.
da).
ights reserved.including acute lymphoblastic leukaemia (ALL) has been validated in
several studies. Mi et al. [11] demonstrated that miR-128a and -128b
are signiﬁcantly overexpressed, and let-7b and miR-223, signiﬁcantly
down-regulated, in ALL patients compared with these expressions in
acute myeloid leukaemia (AML) patients. Zhu et al. [12] also demon-
strated that miR-128 expression is signiﬁcantly higher in ALL patients
compared with that in healthy volunteers. One of the roles of miR-
128a is modulation of the expression of BMI-1, a regulator of self-
renewal of hematopoietic stem cells as well as leukemic cells [13,14].
Although these studies suggest that miR-128a can be a potential onco-
gene contributing to ALL malignancy, the precise roles of miR-128a in
ALL have not been fully understood yet.
Fas-associated proteinwith death domain (FADD) is an adaptor pro-
tein that links the death receptor Fas with procaspase-8 through its
death domain (DD) and death effector domain (DED) for the induction
of apoptosis. One of well-characterised extrinsic apoptosis pathways is
the CD95/Fas signalling pathway. When Fas ligand (FasL) binds to the
death receptor Fas, Fas then binds to the DD of FADD and recruits
procaspase-8 through the DED of FADD to construct the death-
inducing signalling complex (DISC). At DISC, procapsase-8 is activated
by self-cleavage, leading to the activation of downstream caspases
such as caspase-3, cleavage of intracellular substrates such as poly
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Acquisition of resistance to apoptosis is a well-known mechanism in-
volved in tumourigenesis. Although it is well known that cancer cells
often lose sensitivity to Fas-mediated apoptosis through the loss or
down-regulation of Fas or up-regulation of anti-apoptotic molecules
[15,16], FADD deﬁciency was also shown to abolish Fas/FasL-induced
apoptosis in a mouse model [17,18]. Furthermore, the association be-
tween the acquisition of resistance to apoptosis and dysregulated
miRNA expression has been gradually noted recently [19–21].
In this study, we focused on the role of miR-128a in Fas-mediated
apoptosis in human T-cell leukaemia Jurkat cells and demonstrated
that ectopic expression of miR-128a conferred resistance to apoptosis
on Jurkat cells by directly targeting FADD. Furthermore, we validated a
mechanism of miR-128a induction in Jurkat/R cells, which are a Fas-
mediated apoptosis-resistant variant, by conducting methylation-
speciﬁc PCR (MSP) analysis of the promoter region of the intronic
miR-128a gene. Additionally, by antagonizingmiR-128a actionwedem-
onstrated that Jurkat/R cells could be sensitized to Fas-mediated apo-
ptosis. These results demonstrate a novel role of miR-128a and its
epigenetic modiﬁcation in the acquisition of resistance to apoptosis in
leukaemia cells.A
B
Fig. 1. Susceptibility of Jurkat and Jurkat/R cells to Fas-mediated apoptosis stimulated by CH-11
CH-11 at a concentration of 250 ng/mL. PBSwas added in the culturemedium as a control. (B) E
incubation with CH-11 (250 ng/mL) for 1 or 3 h. β-actin was used as an internal control.2. Materials and methods
2.1. Cell culture
Human T-cell leukaemia Jurkat cells (Jurkat) and their Fas-resistant
variant (Jurkat/R), which was obtained after long-term passage under
low-dose Fas stimulation with anti-Fas antibody (CH-11, MBL, Nagoya,
Japan), were grown in RPMI-1640 medium supplemented with
10% (v/v) heat-inactivated FBS and 2 mM L-glutamine under an atmo-
sphere of 95%air and5%CO2 at 37 °C. Humanurinary transitional cell car-
cinoma cell line T24was also cultured in the samemediumandunder the
same conditions for the luciferase assay. Humanacutemyeloid leukaemia
HL60 cells and chronic myeloid leukaemia K562 cells were also grown in
the same medium and under the same conditions. The number of viable
cells was determined by performing the trypan-blue dye exclusion test.
Adherent cells were seeded in 12-well plate at a concentration of
0.5 × 105/mL on the day before experiments and non-adherent
cells were seeded in ﬂasks at a concentration of 1 × 105/mL on the day
before experiments. For induction of apoptosis, CH-11 (MBL) was
added to the medium at the concentration of 0.125–250 ng/mL. 5-Aza
(Sigma, St. Louis, MO) was used for DNA demethylation.treatment. (A) Cell viability of Jurkat and Jurkat/R cells following a 72-h incubation with
xpression of Fas-mediated apoptosis-related proteins in Jurkat and Jurkat/R cells following
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inhibitor for miR-128a
Jurkat and Jurkat/R cells were seeded in ﬂasks at a concentration of
1 × 105/mL (10–30% conﬂuence) on the day before the transfection.
Mature miR-128a (mirVana™miRNA mimic, Applied Biosystems, Fos-
ter City, CA) and antisense inhibitor for miR-128a (mirVana™miRNA
inhibitor, Applied Biosystems) were used for the transfection of the
cells, which was achieved by using cationic liposomes (Lipofectamine
RNAiMAX; Invitrogen, Carlsbad, CA) at the concentration of 20–
40 nM, according to the manufacturer's protocol. The non-speciﬁc con-
trol miRNA (HSS, Hokkaido, Japan) sequence was 5′-GUAGGAGUAGUG
AAAGGCC-3′, which was used as a control for non-speciﬁc effects
[22–24]. The sequence of the mature miRNA-128a was 5′-UCACAGUG
AACCGGUCUCUUU-3′. The effects manifested by the introduction of
these miRNAs into the cells were assessed at the indicated time points
after the transfection.2.3. RNA extraction and quantitative real-time RT-PCR
Total RNA was isolated from cells by using Trizol reagent
(Invitrogen) followed by DNase I treatment. For determination of
mRNA expression levels, total RNA was reverse-transcribed with a
PrimeScript® RT Reagent Kit (TaKaRa, Otsu, Japan). Real-time PCR was
then performed with the primers speciﬁc for FADD, R3HDM1 or
GAPDH by using SYBR® Premix Ex Taq™ (TaKaRa). The sequences of
the primers used in this study were as follows: FADD-sense 5′-ATG
GAC CCG TTC CTG GTG CT-3′, FADD-antisense 5′-TCA GGA CGC TTC
GGA GGT AGA-3′; R3HDM1-sense 5′-GAT GCC AGC CTG TTA TTG CG-A
B
Fig. 2.MinimumCH-11 concentration setting for Jurkat cells. (A) Rate of apoptosis of Jurkat cell
concentration (1/2000) equalled 125 pg/mL. The rate at this concentrationwas not signiﬁcantly
cells following incubation with CH-11 (125 pg/mL) for 8 h. Cell viability at 8 h of incubation w
signiﬁcant, *p b 0.05, ***p b 0.001). The viability rate at 0 h for Jurkat cells was taken as “1.”.3′, R3HDM1-antisense 5′-CTA GGC TCT GAC TCT GGG GT-3′; GAPDH-
sense 5′-CTC AGA CGG CAG GTC AGG TCC ACC-3′, GAPDH-antisense
5′-CCA CCCATGGCA AAT TCC ATGGCA-3′.GAPDHwas used as an inter-
nal control. For determination of mature miR-128a expression levels,
TaqMan®MicroRNAAssays (Applied Biosystems)was used. Quantiﬁca-
tion was normalized to RNU6B expression, which was used as an inter-
nal control. The relative expression levels were calculated by the ΔΔCt
method.2.4. Western blotting
Whole cells were lysed with chilled lysis buffer comprising 10 mM
Tris–HCl (pH 7.4), 1% NP-40, 0.1% deoxycholic acid, 0.1% SDS, 150 mM
NaCl, 1 mM EDTA, and 1% Protease Inhibitor Cocktail (Sigma-Aldrich
Co., St. Louis, MO), and total protein was extracted. Protein contents
were measured with a DC Protein assay kit (Bio-Rad, Hercules, CA).
Lysate proteins were then separated by SDS-PAGE using 7.5–15% poly-
acrylamide gels, electroblotted onto a PVDF membrane (PerkinElmer,
Inc., Boston, MA), and reacted with 1st antibodies speciﬁc for Fas
(MBL), caspase-8 (MBL), caspase-3 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), PARP-1 (Santa Cruz Biotechnology), FADD (Cell Signal-
ling Technology, Inc., Danvers, MA), FLIP (Cell Signalling Technology),
c-Myc (Cell Signalling Technology), CyclinD1 (Cell Signalling Technology),
or CDK4 (Cell Signalling Technology). The 2nd antibodies used were
HRP-conjugated horse anti-mouse or goat anti-rabbit IgG antibody
(Cell Signalling Technology). The signals were visualized by use of
Western Lightning ECL Pro (PerkinElmer). The loading control was pre-
pared by re-incubating the samemembrane with anti-β-actin antibody
(Sigma-Aldrich).s at 8 h after incubation with CH-11 at various dilutions (1/250–1/2000). Themost diluted
different from that for the PBS-treated control cells. (B) Cell viability of Jurkat and Jurkat/R
as not signiﬁcantly different from that at 0 h for both Jurkat and Jurkat/R cells (N.S.: not
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Human urinary transitional carcinoma T24 cells were seeded in
12-well plates at a concentration of 0.5 × 105 per well on the day be-
fore the transfection. Searching the microRNA.org—Targets and Ex-
pression (http://www.microrna.org) to ﬁnd algorithm-based binding




Fig. 3.Effects of CH-11 treatment onmiR-128a expression and apoptosis induction in Jurkat and
and FADD protein expression and PARP-1 cleavage (C) from 0 h to 8 h of incubation of Jurkat a
levels of miR-128a and FADD at 0 h in Jurkat cells were taken as “1.” (D) Effect of miR-128a on F
128a and FADDmRNA from 0 h to 72 h after the transfection of miR-128a at 40 nM (**p b 0.0position 1003–1010 in the 3′UTR of FADD mRNA. The sequence re-
gion 803–1216 containing the putative binding sequence of miR-
128a was inserted into pMIR-REPORT™ Luciferase miRNA Expression
Reporter Vector (Applied Biosystems) according the manufacturer's
protocol. Moreover, we made another pMIR construct encompassing
mutated seed sequence for miR-128a (Wild type, CACTGTG; mutant,
CAACTTG) by using a PrimeSTAR® Mutagenesis Basal Kit (TaKaRa).Jurkat/R cells. Time-course proﬁle ofmiR-128a expression (A), FADDmRNAexpression (B),
nd Jurkat/R cells with CH-11 (125 pg/mL) (*p b 0.05, **p b 0.01, ***p b 0.001). Expression
ADDmRNA stability in Jurkat cells. Time-curse proﬁle of relative expression levels of miR-
1).
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TK Renilla Luciferase Reporter Vector (Promega, Madison, WI) was
used as an internal control vector. T24 cells were co-transfected
with each of the reporter vectors (0.1 μg/well each) and 20 nM
miR-128a or nonspeciﬁc non-coding siRNA (Dharmacon, Tokyo,
Japan), which was achieved by using Lipofectamine™ RNAiMAX
(Invitrogen). Luciferase activities were measured at 48 h after co-
transfection by using Dual-Glo Luciferase Assay System (promega) ac-
cording to the manufacturer's protocol. Fireﬂy luciferase activity was
normalized to renilla luciferase activity.
2.6. DNA extraction and methylation speciﬁc PCR (MSP)
Whole-genome DNA was isolated from Jurkat and Jurkat/R cells by
using DNA lysis buffer (150 mM NaCl, 10 mM EDTA, and 10 mM Tris–
HCl, pH 8.0, 100 μg/ml Proteinase K, 0.1% SDS) followed by RNase A
treatment and PCI extraction. Using the MethylEasy™ Xceed Rapid
DNA Bisulphite Modiﬁcation Kit (TaKaRa), DNA modiﬁcation by
bisulphite conversion was performed. Then, using an EpiScope MSP kit
(TaKaRa), MSP analysis [25] was conducted on Jurkat and Jurkat/R
cells according to the manufacturer's protocol. Episcope unmethylated
HCT116DKO gDNA (TaKaRa) and Episcope methylated HCT116 gDNA
(TaKaRa) were used as a negative control (NC) and a positive control
(PC), respectively. The sequences of the methylated (R3HDM1-M) and
unmethylated (R3HDM1-UM) primers were as follows: 5′-AGG AAG
ATT TGG TAC GGT TTT TC-3′ and 5′-ACC GAC TAT TCA TAA ATT ATA
CGT C-3′ for R3HDM1-M, and 5′-GAG GAA GAT TTG GTA TGG TTT TTT-B
A
Fig. 4.Validation of FADDmRNAas a target gene ofmiR-128a in T24 cells. (A) Predicted binding
Amutant-type pMIR vector was prepared by inserting amutated seed sequence (from CTG to A
or miR-128a and wild-type or mutant-type pMIR vectors having the indicated 3′UTR of FADD (
cells transfected with non-speciﬁc control siRNA (Dharmacon) and those transfected with miR3′ and 5′-ACC AAC TAT TCA TAA ATT ATA CAT C-3′ for R3HDM1-UM.
The PCR reaction conditions were as follows: initial denaturation at
95 °C for 30 s, followed by 40 cycles of denaturation at 98 °C for 5 s, an-
nealing at 53 °C for 30 s, and extension at 72 °C for 1 min. Then, agarose
gel electrophoresis and ethidium bromide staining were performed.
DNAs were visualized by use of a UV transilluminator, and the gel was
photographed with a digital camera. Quantitative MSP was also con-
ducted on Jurkat/R cells according to the manufacturer's protocol. Rela-
tive level of unmethylated DNA (%) was calculated according to the
following formula: unmethylated rate (%) = unmethylated DNA /
(unmethylated + methylated DNAs) × 100.2.7. Construction of FADD expression vector and generation of stable cell
lines by electroporation
Eukaryote pIRES-FADD expression vector was generated by inserting
the open reading frame of FADD cDNA into the EcoR I site of the pIRES
vector (Clontech Laboratories, Inc., Mountain View, CA). Jurkat/R
cells were washed with PBS, suspended in OPTI-MEM® I (Applied
Biosystems), counted, and diluted to a cell density of 1 x 106 of
cells/100 μl. pIRES vector or pIRES-FADD vector (5 μg) were mixed
with 1 x 106 of cells, transferred into pulse cuvettes, and electroporated
by Super Electroporator NEPA21 Type II (NEPAGENE, Chiba, Japan).
After electroporation, an appropriate amount of the complete medium
was added to each aliquot of the cells rapidly. Stable cell lines were se-
lected by G418 (600 μg/ml) containing RPMI medium.site formiR-128a in the 3′UTR region of human FADDmRNA(region A shown as a red box).
CT) for miR-128a into the vector. (B) Luciferase activities after co-transfectionwith control
**p b 0.01). A p value was determined for the difference in luciferase activity between the
-128a.
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All experiments were performed in triplicate. Differences were
statistically evaluated by one-way ANOVA followed by Tukey'sC
A
B
Fig. 5. Cell viability and apoptosis induction affected by ectopic expression ofmiR-128a in Jurkat
in miR-128a-transfected Jurkat cells or antagomiR-128a-transfected Jurkat/R cells at 48 h afte
Jurkat cells were transfected with non-speciﬁc control miRNA or miR-128a (40 nM) for 48 h
pre-transfected Jurkat cells was taken as “1”. Cell viability was signiﬁcantly higher in miR-128
at 8 h after the CH-11 treatment (**p b 0.01). FADD induction and PARP-1 cleavage were supp
pre-transfected Jurkat cells. (D) Jurkat/R cell viability and (E) protein expression of FADD and
miRNA or antagomiR-128a (40 nM) for 48 h, and then treated with CH-11 (1000 pg/mL: 2-fold
miRNA-pre-transfected Jurkat/R cells was taken as “1”. Cell viability was signiﬁcantly lower in a
transfected cells at 8 h after the CH-11 treatment (**p b 0.01). FADD induction and PARP-1 cl
those in control miRNA-pre-transfected ones. Densitometric values are shown for FADD proteimethod, or the unpaired t test. All statistical analyses were
conducted by the GraphPad Prism software system (GraphPad
Software, Inc., La Jolla, CA). A p-value b 0.05 was considered to be
signiﬁcant.cells and by antagonizingmiR-128a in Jurkat/R cells. (A) EndogenousmiR-128a expression
r the transfection. (B) Jurkat cell viability and (C) FADD expression and PARP-1 cleavage.
, and then treated with CH-11 (500 pg/mL) for 8 h. The viability rate of control miRNA-
a-pre-transfected Jurkat cells compared with that in control miRNA-pre-transfected cells
ressed in miR-128a-pre-transfected Jurkat cells compared with those in control miRNA-
of PARP-1 and its cleaved form. Jurkat/R cells were transfected with non-speciﬁc control
severer condition compared with that for Jurkat cells) for 8 h. The viability rate of control
ntagomiR-128a-pre-transfected Jurkat/R cells compared with that in control miRNA-pre-
eavage were increased in antagomiR-128a-pre-transfected Jurkat/R cells compared with
n and the cleaved form of PARP-1 protein. β-actin was used as an internal control.
ED
Fig. 5 (continued).
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3.1. Jurkat/R cells were resistant to caspase-dependent apoptosis induced
by Fas-activating antibody due to dysregulation of FADD and caspase-8
Upon analysing the sensitivity of Jurkat and Jurkat/R cells to Fas-
mediated apoptosis, we showed that our established Jurkat/R cells
were resistant to apoptosis when exposed to Fas-activating antibody
(CH-11), which is a well-known inducer of caspase-dependent apopto-
sis. As shown in Fig. 1A, the viable cell number of CH-11-treated Jurkat
cells was almost 0 at 24 h after the start of CH-11 treatment. In contrast,
the number of viable CH-11-treated Jurkat/R cells increased with time,
as did the PBS-treated control population (Fig. 1A). To understand the
mechanism of the observed resistance to CH-11 in Jurkat/R cells, we
analysed the expression of Fas/FasL signalling-related proteins in Jurkat
and Jurkat/R cells after the treatment with CH-11. In Jurkat cells, the in-
duction of FADD was observed after 1 h of CH-11 treatment (Fig. 1B).
Caspase-8 and caspase-3 were activated at almost the same time that
FADD was induced (Fig. 1B). The cleaved form of PARP-1, an indicator
of apoptosis, also emerged at 1 h of incubation with CH-11 (Fig. 1B).
However, in Jurkat/R cells, the expression level of FADDwas almost un-
changed, and caspase activities and PARP-1 cleavage were barely ob-
served at 3 h of CH-11 treatment (Fig. 1B). The expression level of the
pro-caspase-8 in Jurkat/R cells was lower than that of Jurkat cells at
their steady state (Fig. 1B). The expression level of FLIP, an anti-
apoptotic protein [26], was unchanged after treatment of either cell
line with CH-11 (Fig. 1B). As a result, we conﬁrmed that these Jurkat/R
cells were resistant to Fas-induced apoptosis because of the decreased
induction of FADD and decreased expression of pro-caspase-8 (Fig. 1B).3.2. MiR-128a directly targeted FADD
The aim of this study was to validate the role of miR-128a in leukae-
mia and elucidate its functional relevance to the resistance to Fas-
mediated apoptosis. Based on the result of microRNA.org (http://
www.microrna.org), a predicted binding site for miR-128a was found
at position 1003–1010 in the 3′UTR of human FADD mRNA. Though
caspase-8 is considered to be essential for apoptosis induction by Fas,
FADD is also obligatory adaptor protein in the Fas/FasL signalling path-
way [27]. Therefore, we decided to focus on the roles of miR-128a and
FADD in Jurkat and Jurkat/R cells during Fas-mediated apoptosis. First
of all, we set the optimum concentration of CH-11 at which apoptosis
would be induced not drastically but slowly and viable cell counts
would not greatly differ between Jurkat and Jurkat/R cells. We set
250 ng/mL of CH-11 (used in Fig. 1) as the initial concentration, and di-
luted it 1/2000 (to 125 pg/mL). After an 8-h treatment with CH-11 at
various diluted concentrations, the rate of apoptosis was calculated
for the CH-11- susceptible Jurkat cells (Fig. 2A). The apoptotic cell
rate of Jurkat cells treated with 125 pg/mL of CH-11 for 8 h was not sig-
niﬁcantly different from that of the non-treated control (Fig. 2A). At this
concentration, the viable cell rate was almost the same between Jurkat
and Jurkat/R cells at 8 h (Fig. 2B). Thus, we determined 125 pg/mL of
CH-11 as the minimum concentration that could potentiate the induc-
tion of apoptosis but maintain the cell viability of the Jurkat cells.
Next, we examined the expression level of miR-128a in Jurkat and
Jurkat/R cells during Fas-mediated apoptosis stimulated by 125 pg/mL
CH-11. As shown in Fig. 3A, miR-128a expression was signiﬁcantly de-
creased in Jurkat cells and, conversely, signiﬁcantly increased in
Jurkat/R cells, at 8 h of CH-11 treatment. At steady state (0 h), the
A B
C
Fig. 6. Overexpression of FADD in Jurkat/R cells and CH-11 susceptibility. (A) Cell viability of Jurkat/R cells introduced with pIRES control vector or pIRES-FADD vector (**p b 0.01).
(B) FADD and cell cycle-related protein expressions in Jurkat/R cells introduced with pIRES control vector or pIRES-FADD vector. (C) Cell viability of Jurkat/R cells introduced with
pIRES control vector or pIRES-FADD vector at 24 h after the CH-11 treatment (1000 pg/mL).
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higher than that in Jurkat/R cells (Fig. 3A). Given the inverse correlation
ofmiR-128a expression between CH-11-susceptible and -resistant cells,
we investigated whether miR-128a inhibited Fas-induced apoptosis
through the inhibition of FADD expression. As shown in Fig. 3B, we
found increased transcription of FADD mRNA in both cell lines after
the CH-11 treatment. However, the protein level of FADD was not in-
creased in Jurkat/R cells compared with that in Jurkat cells (Fig. 3C). In
Jurkat cells, PARP-1 cleavage was observed at 4 h of CH-11 treatment;
however, in Jurkat/R cells, it was barely observed even after 8 h of CH-
11 treatment (Fig. 3C). Since FADD protein level and mRNA level were
not consistent with each other at 4 and 8 h after the CH-11 treatment,
effect of miR-128a on FADD mRNA stability was also examined
(Fig. 3D). We found 10 to 24 hours' time lag between the up-
regulation ofmiR-128a and down-regulation of FADD. Therefore, the in-
creased expression of miR-128a was indicated to play a possible role in
the translational repression of FADD expression through RNA interfer-
ence, and in the resistance to the Fas-induced apoptosis in Jurkat/R
cells. To further conﬁrm FADD as a target gene of miR-128a, we cloned
the 3′UTR of FADD mRNA, the sequence region 803–1216 containing
the predicted binding sequence of miR-128a (region A) into the down-
stream region of the ﬁreﬂy luciferase gene in the pMIR-REPORT vector
(pMIR-region A) (Fig. 4A). As expected, compared with that of the con-
trol, the luciferase activity of the wild-type pMIR-region A was signiﬁ-
cantly inhibited after the introduction of miR-128a into the T24 cells
(Fig. 4B). Furthermore, mutation of the FADD 3′UTR-binding site in
region A abolished the ability of miR-128a to regulate luciferaseexpression (Fig. 4B). These results demonstrated FADD to be a potential
target of miR-128a in Jurkat and Jurkat/R cells.
3.3. Ectopic expression of miR-128a in Jurkat cells diminished their
sensitivity to the Fas-induced apoptosis
To further explore the role of miR-128a in Fas-induced apoptosis in
leukaemia cells, we investigated whether the down-regulation of miR-
128a in Jurkat cells may have contributed to their Fas susceptibility.
First of all, we conﬁrmed that endogenous miR-128a expression levels
were signiﬁcantly increased or decreased in miR-128a-transfected
Jurkat cells or antagomiR-128a-transfected Jurkat/R cells, respectively,
at 48 h after the transfection (Fig. 5A). Next, when non-speciﬁc control
miRNA- or miR-128a-transfected Jurkat cells were incubated with CH-
11 at the concentration of 500 pg/mL for 8 h, the latter showed a signif-
icantly increased cell viability compared with the former (Fig. 5B). Fur-
thermore, in the presence of CH-11, the induction of FADD expression
and cleavage of PARP-1 were also decreased in Jurkat cells transfected
with miR-128a compared with the levels for the control transfected
cells (Fig. 5C).
3.4. Antagonizing of miR-128a expression sensitized Jurkat/R cells to the
Fas-induced apoptosis
Moreover, we investigated the contribution of miR-128a to the
Fas resistance in Jurkat/R cells. When control or antagomiR-128a
transfected Jurkat/R cells were incubated with CH-11 at the
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cells showed a signiﬁcantly decreased cell viability compared with the
control transfected cells (Fig. 5D). Furthermore, the induction of FADD
expression and cleavage of PARP-1 were also increased in antagomiR-
128a transfected cells in the presence of CH-11 compared with the
levels for the non-speciﬁc control miR-transfected cells (Fig. 5E).
3.5. Overexpression of FADD in Jurkat/R cells promoted cell proliferation
instead of increasing the susceptibility to the CH-11 treatment
If FADD expression was crucial for the cytotoxicity of CH-11 on
Jurkat cells, overexpression of FADD could sensitize Jurkat/R cells to
the CH-11 stimulation.We generated a stable line of Jurkat/R cells over-
expressing FADD and examined the cytotoxic effect of CH-11 on them.
As shown in Fig. 6, FADD overexpression promoted cell proliferation
and up-regulated c-Myc expression in Jurkat/R cells instead of increas-
ing the susceptibility to the CH-11 treatment (1000 pg/mL for 24 h).
3.6. Increased expression of miR-128a and consequent inhibition of FADD
induction was attributed to the DNA demethylation of its promoter region
in Jurkat/R cells
We further investigated the induction mechanism of miR-128a ex-
pression following CH-11 treatment in Jurkat/R cells. MiR-128a is
an intronic gene, which resides within the R3HDM1 (R3H domain con-
taining 1) gene on chromosome 2q21 based on the UCSC Genome
Bioinformatics (http://genome.ucsc.edu/). Based on the database, we
considered miR-128a shares the promoter region of its host gene. In
cancer cells, DNA methylation in the promoter region is known to be a
signiﬁcant machinery of gene regulation. Therefore, we investigated
the methylation status in the promoter region of the R3HDM1 gene by
using the MSP method [25] and found that the promoter region of
R3HDM1was methylated only in Jurkat/R cells (Fig. 7A). We also con-
ﬁrmed that CH-11 treatment signiﬁcantly increased the R3HDM1
mRNA expression level in Jurkat/R cells (Fig. 7B), and quantitative
MSP revealed that partial demethylation of the promoter region of
R3HDM1 gene was induced by CH-11 treatment in Jurkat/R cells
(Fig. 7C). 5-Aza treatment also signiﬁcantly increased the R3HDM1
mRNA expression level in Jurkat/R cells (Fig. 7D), and up-regulated
miR-128a expression in Jurkat/R cells (Fig. 7E) and consequently
inhibited FADD expression (Fig. 7F).
3.7. miR-128a-mediated FADD down-regulation and Fas-resistance were a
general mechanism including myeloid leukaemia cells
We further examined whether miR-128a-mediated FADD down-
regulation contributed to the Fas-resistance of acute and chronic mye-
loid leukaemia cells (AML and CML cells). As shown in Fig. 8A, AML
cell line HL60 cells and CML cell line k562 cells were highly resistant
to the CH-11 treatment. As a possible mechanism of the resistance,
up-regulation of miR-128a expression and inhibited induction of
FADD protein were indicated in both cell lines (Fig. 8B and C).
4. Discussion
Previous studies by Mi et al. [11] and Zhu et al. [12] demonstrated
thatmiR-128a and -128b are up-regulated in ALL bonemarrow samplesFig. 7.Methylation status of miR-128a promoter region in Jurkat and Jurkat/R cells, effects of CH
FADD. (A) Genomic DNA extracted from Jurkat and Jurkat/R cells was ampliﬁed by MSP (m: m
moter region for R3HDM1was evaluated in Jurkat and Jurkat/R cells. NC indicates a negative-con
control with highly methylated genomic DNA. (B) Effect of CH-11 treatment on R3HDM1 expr
GAPDHwas used as an internal control. (C) Quantitative MSP in Jurkat/R cells treated with CH-
uated. (D) Effect of 5-Aza treatment on R3HDM1 expression in Jurkat and Jurkat/R cells (0–1.0 μM
Jurkat and Jurkat/R cells. RNU6B and β-actin were used as internal controls (N.S.: not signiﬁcanand cell lines compared with their levels in AML samples or normal
bone marrow controls. They also showed that miR-128 overexpression
in ALL is not associated with DNA ampliﬁcation of their genomic loci
(miR-128a at 2q21 and miR-128b at 3q22). Furthermore, they sug-
gested that epigenetic regulation, especially methylation of the CpG
islands of miR-128b, may be associated with the differential expression
of miR-128b between ALL and AML, as the methylation rate was much
less in ALL samples than in AML samples. However, showing the meth-
ylation rates in ALL and normal control samples were not signiﬁcantly
different, they suggested the existence of another mechanism control-
ling miR-128 expression. As regards the biological roles of miR-128, it
was also reported that miR-128 regulates the chemotherapeutic sensi-
tivity of breast cancer through targeting Bmi-1 and ABCC5, and/or con-
tributes to the impaired apoptotic response of endometrial cancer cells
by modulating FOXO1 expression [28,29]. These previous studies sug-
gest an oncogenic potential of miR-128a; however, the underlying
mechanisms of its function in ALL have not been validated yet. In
the current study, we demonstrated a novel role of miR-128a in T-cell
leukaemia Jurkat cells through validation of an apoptosis-resistance
mechanism, especially against Fas-mediated apoptosis-resistance
mechanism. First of all, we constructed CH-11 resistant Jurkat cells
named Jurkat/R cells, and validated its resistance was attributed to the
impaired pro-caspase-8 expression and decreased induction of FADD
following Fas stimulation. CH-11 treatment also induced Fas up-
regulation in Jurkat/R cells. It indicated a presence of feed-backmachin-
ery. When CH-11 stimulates Fas of Jurkat/R cells at steady state, the ap-
optosis signalling was mediated by the impaired FADD and caspase-8
expression, and that might lead to the up-regulation of Fas by a certain
feed-backmachinery to urge apoptosis. Both the impaired expression of
pro-caspase-8 and decreased induction of FADD were considered to be
responsible for the Fas resistance in Jurkat/R cells. However, since
FADD was found in the database as a possible target gene of miR-128a,
we focused on the roles of FADD and miR-128a in the Fas resistance.
As a role of FADD, if decreased induction of FADD was responsible for
the resistance, FADD overexpression could have made Jurkat/R cells be
susceptible to the Fas stimulation. However, the overexpression of
FADD promoted cell growth instead of increasing the susceptibility to
the Fas stimulation in Jurkat/R cells. It was considered that besides
being a key adaptor protein transmitting apoptotic signals mediated
by Fas, FADD is also known to be required for T cell proliferation [30].
So far, FADD-mediated T-cell proliferation pathway is unknown, how-
ever, our data was consistent with that FADD has a certain role in the
cell cycle progression.
The present study showed that the endogenous level of miR-128a in
Fas-resistant Jurkat/R cells was about 2–3 fold lower than that in Jurkat
cells. Following incubation with CH-11, the induction and the repres-
sion of miR-128a expression occurred inversely in Jurkat and Jurkat/R
cells; i.e., miR-128a was down-regulated in Jurkat cells and up-
regulated in Jurkat/R cells. Consequently, whereas FADD induction oc-
curred smoothly in Jurkat cells, FADD expression was repressed in
Jurkat/R cells, resulting in the delayed induction of apoptosis. These
ﬁndings suggested that a dynamic state of miR-128a expression level
could have relevance to the induction of FADD rather than the endoge-
nous level itself. Furthermore, we conﬁrmed that AML HL60 cells and
CML K562 cells were both resistant to the CH-11 treatment like
Jurkat/R cells. The mechanism of their resistance was also suggested
partially to be the up-regulation of miR-128a and decreased induction
of FADD expression. We further demonstrated that antagomiR-128a-11 and 5-Aza on R3HDM1 expression, and effect of 5-Aza on expression of miR-128a and
ethylated-speciﬁc PCR, u; unmethylated-speciﬁc PCR). The methylation status of the pro-
trol genomic DNA, of which themethylation levelswere extremely low; and PC, a positive
ession in Jurkat and Jurkat/R cells. Cells were incubated with CH-11 (125 pg/mL) for 8 h.
11 at 125 pg/mL for 8 h. Unmethylated rate in the promoter region for R3HDM1was eval-
for 24 h). (E) Effect of 5-Aza treatment on expression levels ofmiR-128a and (F) FADD in
t, *p b 0.05, **p b 0.01, ***p b 0.001).
AB
C
Fig. 8. Effects of CH-11 treatment onmiR-128a expression and FADD induction in AML HL60 cells and CML K562 cells. (A) Cell viability, (B)miR-128a expression and (C) FADD expression
and PARP-1 cleavage at 24 h after the CH-11 treatment at indicated concentration (*p b 0.05, **p b 0.01, ***p b 0.001). RNU6B and β-actin were used as internal controls.
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Fig. 9. Proposedmodel for the involvement ofmiR-128a in the Fas/FasL apoptotic pathway.MiR-128a expression ismodulated by Fas/FasL signalling and regulates FADD expression.MiR-
128a directly targets FADDmRNA. In Fas-susceptible cells, miR-128a is down-regulated and FADD repression is cancelled following Fas stimulation, thus leading to smooth induction of
apoptosis. In Fas-resistant cells, on the contrary,miR-128a is up-regulated and FADD remains repressed following Fas stimulation, resulting in delayed or decreased induction of apoptosis.
Demethylation of the promoter region for miR-128a contributes to the miR-128a up-regulation, inhibition of FADD expression, and consequent Fas-resistance.
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derepression of FADD expression, aswas evidenced by decreased cell vi-
ability and increased PARP-1 cleavage. In Jurkat cells, on the other hand,
we couldmake them resistant to the Fas-mediated apoptosis by ectopic
expression of miR-128a, which led to the inhibition of FADD induction,
conﬁrmed by increased viability and decreased PARP-1 cleavage. These
ﬁndings strongly indicate FADD to be an indispensable adaptor protein
for the induction of Fas-mediated apoptosis and also suggest that antag-
onizing miR-128a in apoptosis-resistant cells could be a new strategy
for treatment of ALL.
This study also demonstrated that up-regulation of miR-128a and
consequent resistance to the Fas-mediated apoptosis in Jurkat/R cells
was mediated by demethylation of the promoter region for intronic
miR-128a. The promoter region of R3HDM1, which is the host gene of
intronic miR-128a, wasmethylated only in Jurkat/R cells, which ﬁnding
explains the lower endogenous level of miR-128a in Jurkat/R cells than
in Jurkat cells. CH-11 treatment increased the expression of R3HDM1
and miR-128a in Jurkat/R cells, as did the demethylating agent 5-Aza,
indicating that Fas stimulation promoted the DNA demethylation pro-
cess. However, mechanisms involved in the demethylation process re-
main unclear at this time. In Jurkat cells, on the contrary, the promoter
region of R3HDM1 was not methylated; and treatment with CH-11
signiﬁcantly decreased miR-128a expression. We hypothesized that in-
creased DNA methylation might have been a cause of miR-128a down-
regulation. To conﬁrm this hypothesis, we examined the expression
level of host gene R3HDM1; however, R3HDM1 expression in Jurkat
cells was unchanged after the treatment with CH-11. These ﬁndings in-
dicate thatmiR-128a expression alsomight be regulated by somemech-
anism(s) other than DNA methylation.
As a summary, we here proposed a model of miR-128a-mediated
regulation of Fas-mediated apoptosis signalling (Fig. 9). In Fas-resistant cells, demethylation and consequent up-regulation of miR-
128a following the Fas stimulation inhibits FADD induction by directly
binding to its 3′UTR, resulting in the delayed induction of apoptosis. In
Fas-susceptible cells, the down-regulation of miR-128a following the
Fas stimulation frees FADD induction from repression, thus leading to
the smooth induction of apoptosis.
Therapeutic strategies for leukaemiaswith resistance to chemother-
apeutic agents are urgently needed. Our ﬁndings raise the possibility
of future use of antagomiR-128a as a chemosensitising agent for
apoptosis-resistant cancers with impaired FADD induction. Further
studies are needed to validate the regulatory role of miR-128a in apo-
ptosis signalling and also the modulators of the miR-128a methylation
status activated by Fas treatment.Acknowledgement
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